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RanolazineIn this article we review the late Na current which functionally can bemeasured using patch-clamp electrophys-
iology (INa,late). This current is largely enhanced under pathological myocardial conditions such as ischemia and
heart failure. In addition, INa,late can cause systolic and diastolic contractile dysfunction via a Na-dependent
Ca-overload of the myocyte. Moreover, INa,late plays a crucial role as ventricular and atrial proarrhythmic sub-
strate in myocardial pathology by changing cellular electrophysiology. We summarize recent experimental
and clinical studies that investigate therapeutic inhibition of this current and discuss the signiﬁcance of the avail-
able data and try to answer not only the question, where we currently are but also where wemay go in the near
future. This article is part of a Special Issue entitled “Na+ Regulation in Cardiac Myocytes”.
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Sarcolemmal Na channels are responsible for the cardiac Na current
(INa). Na channels mainly open transiently and are quickly inactivated
thereby carrying the large peak Na current (INa,peak) which initiates the
well-known steep upstroke of the action potential (AP). A small compo-
nent of INa was named persistent or late Na current (INa,late) because of
Na channels that remain active, inactivate with slower kinetics, or even
reopen. The amplitude of INa,late is very small compared to the INa,peak inologie/Herzzentrum, Deutsches
ität Göttingen, Robert-Koch-Str.
: +49 551 39 14131.
Maier).
rights reserved.normal myocardium (~0.5% of INa,peak) [1] but may persist for hundreds
of milliseconds. Coraboeuf et al. measured APs in dog Purkinje ﬁbers
and found that tetrodotoxin (TTX) abbreviated these at concentrations
lower than those at which the maximum rate of AP upstroke decreased
[2]. This ﬁnding leads them to conclude that this current “ﬂows through
a background Na conductance or/and a small proportion of Na channels
with no inactivation mechanism (or inactivation mechanism different
from normal)” which means that these authors discovered INa,late [2].
Moreover, also in 1979 Attwell and coworkers described an INa,late in
their experiments as a current which extends to potentials well into the
range of the action potential plateau and elegantly concluded: “Conse-
quently small changes of the steady state INa might have large effects on
the action potential duration” [3].
Since then, INa,late was found to be elevated under several cardiac
pathological conditions [4–7] and it was suggested that this may
lead to intracellular Na-overload [8–10]. In addition, INa,late can be
Fig. 1.Vicious circle ofmyocardial ischemiawith a focus on INa,late: Ischemia enhances INa,late
which increases intracellular Na+ and Ca2+ via Na+/Ca2+ exchanger (NCX). As a conse-
quence, Ca ions overactivatemyoﬁlamentswhich aggravatesmyocardial ischemia. Blockers
of INa,late are capable to attenuate this pathological cascade.
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slow the rate of INa inactivation [7,11–13]. Interestingly, mutations in
the Na channel gene SCN5Awhich is associatedwith the long QT-3 syn-
dromeproduce slowed inactivation thereby increasing INa,late [14]. Most
importantly and of clinical relevance are disease states such as hypoxia,
ischemia/reperfusion,myocardial infarction, and heart failure that were
shown to be associated with an elevated INa,late [4,15,16]. Almost ﬁfteen
years ago, Ahern and colleagues have shown that nitrosylation of
SCN5A increases INa,late under physiological and pathophysiological
conditions [17]. Over the last few years, Ca/calmodulin-dependent
kinase II (CaMKII) was found to associate and phosphorylate the cardiac
Na channel which is critically involved in Na channel gating, e.g. by
increasing INa,late [18–22]. Interestingly, CaMKII activation occurs in a
couple of myocardial pathological conditions where INa,late is also ele-
vated (e.g. heart failure and atrial ﬁbrillation) [23]. (For the details of
the molecular mechanisms underlying the origins of the INa,late see re-
view by Moreno and Clancy [24]).
In addition to the toxin TTX [25], the clinically approved
anti-ischemic drug ranolazine was found to inhibit INa,late [26]. In
cardiac myocytes from dogs and guinea pigs, ranolazine caused a
concentration-, voltage-, and frequency-dependent INa,late inhibition
[27]. It was suggested that ranolazine binds at the putative local anes-
thetic binding site of the cardiac speciﬁc Na channel isoform Nav1.5
[14]. But it remains unclear how this compound produces its selectiv-
ity on INa,late. Inhibitory effects of ranolazine on INa,late were demon-
strated in multicellular myocardium and in isolated myocytes
[11,13,28]. Ranolazine has also weak INa,peak inhibiting effects, howev-
er with up to 38-fold higher potency for INa,late than INa,peak with an
IC50 of 6.5 vs. 244 μM in dog ventricular myocytes [28]. Ranolazine
was also shown to have some weak inhibitory effects on the peak
and late L-type Ca current with an IC50 of 296 μM and 50 μM, respec-
tively [27]. Within the therapeutic concentration range which varies
between 2 and 8 μM, ranolazine inhibits the late L-type Ca current
by 25–30% but at 10 μM by ~70% [27]. Thus, this could amount to
non-negligible reduction in the net Ca inﬂow during the action poten-
tial and hence has to be taken in account with respect to antiischemic,
antiarrhythmic, and effects on the failing myocardium of ranolazine.
Finally, ranolazine may also have beneﬁcial effects on Nav1.5 since it
was very recently shown that it inhibits stretch-induced modulation
of Nav1.5 [29,30].
There are also other drugs that can preferentially inhibit INa,late
such as the class I antiarrhythmic drugs lidocaine, mexiletine, and
ﬂecainide, and the class III antiarrhythmic drug amiodarone [31].
Recently, a novel potent and selective inhibitor INa,late GS967 (6-[4-
(triﬂuoromethoxy)phenyl]-3-(triﬂuoromethyl)-[1,2,4]triazolo[4,3-a]
pyridine) was described which is currently further investigated ex-
perimentally and possibly soon clinically. F 15845 is another new
compound which selectively inhibits INa,late as shown by measure-
ments in HEK293 cells [32].
2. INa,late in myocardial ischemia
An accumulation of metabolites such as palmitoyl-L-carnitine,
lysophosphatidylcholine, and reactive oxygen/nitrogen species occurs
during myocardial ischemia and reperfusion thereby increasing INa,late
[5,6] thus causing intracellular Na overload [9,13]. Inhibition of INa,late
reduces the rise in [Na]i [12,13]. Usually, elevated Na levels lead to
intracellular Ca overload due to reduced efﬂux of Ca-ions through the
forward mode of the Na/Ca-exchanger (NCX) and/or a larger inﬂux of
Ca-ions through the reverse mode of the NCX. In addition to changes
in [Na]i and [Ca]i, the NCX also produces an electrogenic current and
hence generates an electrical potential because three Na ions are ex-
changed for each Ca ion [33]. Na accumulation and prolonged AP dura-
tion are known to be potent triggers of reverse mode NCXwhich occurs
during myocardial hypoxia [8]. The result is an impaired overall capac-
ity of the cell to eliminate Ca. This leads to contractile protein activationand hypercontraction of cardiac myocytes [34]. As a result, increased
wall tension occurs which induces compression of intramural vessels
leading to impaired oxygen supply (see Fig. 1) [35].
Themajority of experimental studies that investigated the relevance
of INa,late modulation with respect to myocardial ischemia are derived
from experiments using ranolazine. Ranolazine and TTX reverse the
rise in [Na]i caused by simulated ischemia, ATX-II and oxygen free rad-
icals [12,13,36]. Moreover, inhibition of INa,late reduces reverse mode
NCX and consequently diastolic Ca accumulation during ischemia/
reperfusion and in the presence of ischemic metabolites, ATX-II, and re-
active oxygen species [12,13,37]. The net result is an improved diastolic
function [13,38–41]. A recent clinical study investigated ranolazine in
patients with coronary heart disease subjected to quantitative analysis
of serial myocardial perfusion images and found a reduced perfusion
defect sizes during exercise and thus improved myocardial perfusion
[42]. A reduced diastolic wall tension is regarded to decrease oxygen
consumption and ATP utilization due to reduced myoﬁlament activity
and lower diastolic Ca levels. Ranolazine has been shown to counteract
the decrease in tissue ATP in an isolated rabbit heartmodel of ischemia/
reperfusion [43]. This observation was paralleled by an improved LV
pressure, reduced release of creatine kinase, and less reperfusion injury.
The safety and efﬁcacy of ranolazine are well investigated and its
use as an antianginal agent was clinically established. An early study
compared atenolol and ranolazine in patients who had limited exer-
cise capacity due to symptomatic angina pectoris in a randomized
double-blind, placebo-controlled crossover study [44]. Treatment with
ranolazine or atenolol improved time onset of angina and ST-segment
depression. In addition, ranolazine increased exercise duration compared
to atenolol. Unlike atenolol, the effects of ranolazine occurred without
changes of the rate-pressure product indicating that the antiischemic ef-
fect of ranolazine does not depend on a decrease in cardiac work. Further
studies such as MARISA, CARISA und ERICA were performed in order to
investigate the sustained release formulation of ranolazine (for review
see [26]).
The MERLIN TIMI-36 trial investigated the effect of clinical outcome
and safety of ranolazine therapy in >6000 acute coronary syndrome
(ACS) patients [45]. Treatment with ranolazine did not signiﬁcantly
reduce the composite primary combined endpoint of cardiovascular
death, myocardial infarction, or recurrent ischemia. Nevertheless,
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rent ischemia. Although the ﬁndings of MERLIN do not indicate the use
of ranolazine for acute management of ACS patients the results demon-
strate safety and underline the beneﬁt of ranolazine as an antianginal
agent for a broad population of patients with angina pectoris.
3. Contractile dysfunction — heart failure
Cellular Na and Ca handling is important for the regulation of
myocardial contractile function. An excessive accumulation of intra-
cellular Ca is known to induce diastolic and systolic dysfunction. Ca
overload can be linked to an elevation of [Na]i caused in part by an
enhanced INa,late. Indeed, INa,late has been shown to be largely elevated in
the pathology of heart failure [15,18,41,46,47]. Therefore, it was hypothe-
sized that the inhibition of this current attenuates LVmechanical dysfunc-
tion (systolic and diastolic) in the failing heart by a similar mechanism as
it is explained above for myocardial ischemia.
Two experimental studies report on beneﬁcial effects of INa,late
inhibition using ranolazine in vivo in canine heart failure models. In
dogs with coronary microembolization-induced heart failure acute
infusion of ranolazine reduced LVEDP but increased LV ejection fraction
and stroke volume [48]. In the samemodel, ranolazinewas investigated
as a chronic treatment option in combination with metoprolol or enala-
pril [40]. Ranolazine prevented progressive LV dysfunction as well as
global and cellularmyocardial remodeling. In combinationwith enalapril
or metoprolol ranolazine improved LV function beyond that observed
with ranolazine alone.
We examined isolated myocardial trabeculae from human end-stage
failing hearts that exhibited frequency-dependent diastolic dysfunction
[13] (see Fig. 2). Ranolazine did not cause negative inotropy but reduceda
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Fig. 2. Improvement of diastolic function in human failing myocardium: Effects of 10 μmol/
muscles from end-stage failing human hearts. (a) Original recordings of force at 0.5 and 3 Hz
panels). (b) Mean data for diastolic tension (n = 14 each), pb0.05 (ANOVA).
Modiﬁed from Sossalla et al., JMCC, 2008the increase in diastolic tension, i.e. improved diastolic dysfunction. In a
non-ischemic heart failure model we isolated papillary muscles from
transgenic mice overexpressing CaMKII [49]. Exposure to ranolazine
markedly reduced present diastolic dysfunction under frequency-
induced stress suggesting that CaMKII which can induce INa,late may
be activated by increased Ca levels (and hence Ca overload) [13,41].
Indeed, the direct effects of CaMKII on Na channels (and thus INa,late)
were reportedpreviously [18] and even effects of reactive oxygen species
on INa,late were shown to be mediated by CaMKII [50].
The underlying mechanism causing improved contractile function
in heart failure due to inhibition of INa,late was investigated in isolated
cardiomyocytes which were exposed to ATX-II [13]. The increase in
cytosolic Na was paralleled by an elevated diastolic [Ca]. Treatment
with ranolazine attenuated the effects of ATX-II leading to markedly
reduced diastolic Ca levels and lower Na levels. We consider an in-
crease in NCX forward mode as the link between cytosolic Na and
Ca. However, there is a need for future studies that should investigate
the inﬂuence of INa,late modulation on NCX function and transport
direction especially in cardiac pathology. Our ﬁndings with respect
to improved diastolic function are consistent with the studies in ani-
mals showing that ranolazine attenuates diastolic dysfunction during
ischemia/reperfusion [37,43], in the presence of ischemic metabolites
[51], or reactive oxygen species [52], and in dogs with heart failure
[28]. In summary, most of the experimental studies in heart failure
models report on beneﬁcial effects on diastolic performance than on
positive inotropic effects.
In contrast to the large experimental knowledge, clinical investi-
gations on INa,late in patients suffering from heart failure are limited.
In 1994, there was a ﬁrst in vivo study showing an improved diastolic
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L ranolazine (Ran) on diastolic tension during stepwise increases in stimulation rate in
during control conditions (vehicle, left panels) and in the presence of ranolazine (right
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acute infusion of ranolazine in patients with type-3 long-QT syn-
drome where INa,late is increased caused an improvement in diastolic
relaxation [54]. We performed the ﬁrst prospective, randomized,
double-blind, placebo-controlled small proof-of-concept study in 20
patients with diastolic heart failure and showed that ranolazine im-
proved measures of hemodynamics including LVEDP and PAP, but
there was no improvement in relaxation parameters [55]. Coppini
and coworkers recently investigated functional changes in myocardium
from human hypertrophic cardiomyopathy, showing a complex remod-
eling process involving alterations of CaMKII-dependent signaling, rather
than being a direct consequence of the causing sarcomeric mutations
[56]. They found an enhanced INa,late to be amajor contributor to the elec-
trophysiological abnormalities of ventricular myocytes and trabeculae
from these patients, suggesting a potential therapeutic role of INa,late inhi-
bition. These ﬁndings are the basis for the recently initiated pilot study
RESTYLEwhich investigates ranolazine in patientswith symptomatic hy-
pertrophic cardiomyopathy with respect to exercise capacity, diastolic
function, and symptomatic status (EudraCT-Nr. 2011-004507-20).
Taken together, there is an increasing evidence that the inhibition
of INa,late using ranolazine may have a future therapeutic role for the
treatment of systolic and diastolic heart failure. Since there is not
one evidence-based compound for the treatment of diastolic heart
failure up to date further clinical trials are indicated to evaluate the
safety and efﬁcacy of INa,late inhibition in patients with diastolic, and
possibly systolic heart failure.4. INa,late and ventricular arrhythmias
An elevated INa,late is potentially involved in ventricular and atrial
arrhythmogenesis by changing cellular electrophysiology. Early
afterdepolarizations (EADs) aremore likely to occur during a prolonged
AP as a possible consequence of increased INa,late [11]. Transmural differ-
ences of INa,late and hence AP duration might increase dispersion of
repolarization and QT interval, which underlies the development of tor-
sade de pointes tachyarrhythmias [57].
Independent of AP prolongation, Ca overload resulting from elevated
INa,late [13], and leakiness of the ryanodine receptor are believed to partic-
ipate as crucial events in the initiation and propagation of spontaneous
SR Ca release events [33]. The consequence may be the elimination of
cytosolic Ca via NCX which generates a depolarizing current (transient
inward current, ITi) giving rise to delayed afterdepolarizations (DADs)
[58]. The crucial importance of INa,late for arrhythmias was demonstrated
in guinea pigmyocytes [59]. An increased INa,late leads to development of
EADs and DADs as well as triggered activity through ITi. These effects
could be suppressed by ranolazine or TTX. Ca chelating agents, NCX
blockers and the SR Ca release inhibitor ryanodine could prevent DADs
and triggered activity. Since EADs could not be prevented using these
agents, it is suggested that the prolongation of AP causes EADs in a
Ca-independent manner.
There are several reports showing potent antiarrhythmic effects of
INa,late inhibition in ventricular cardiomyocytes and tissue. Ranolazine
has demonstrated striking effects on afterdepolarizations as arrhythmic
triggers and the transmural and temporal dispersion of repolarization in
models with elevated INa,late [11,28,60,61]. Ranolazine prevented
pacing-induced re-entrant and multifocal ventricular ﬁbrillation [62].
Ranolazine also inhibits IKr [27]which causes alone a prolongation of
the ventricular AP, whereas the inhibition of INa,late has the opposite ef-
fect and abbreviates AP. Thus, the net effect of ranolazine onAPduration
is driven by the relativemagnitude of INa,late (inward) and IKr (outward)
currents during the repolarization period. Ranolazine inhibits IKr with a
potency of ~11.5 μM, but only weakly interacts with ICa (~300 μM) or
NCX (~90 μM) [27]. Therefore, we consider INa,late as the major target
of ranolazine for the prevention and termination of ventricular arrhyth-
mias. Of note, another new antiischemic compound F 15845 whichblocks INa,late was effective at preventing fatal ventricular ﬁbrillation
and ventricular tachycardia during coronary ligation [32].
Interestingly, there are studies showing antiarrhythmic effects of
ranolazine under conditions without elevated INa,late as it was
shown for IKr blocker-induced arrhythmogenic triggers and arrhyth-
mias [27,63–65]. INa,late is largest in midmyocardial myocytes, that
can be characterized by having APs that prolong disproportionately
compared to the APs of other left ventricular cell types in response
to many QT-prolonging drugs [66,67]. These cardiomyocytes are
more likely to develop EADs in response to triggers that reduce the
repolarization reserve. Accordingly, it was shown that ranolazine in-
duces a preferential abbreviation of midmyocardial cell AP duration
(where INa,late is most prominent), causing a reduction in transmural
dispersion of repolarization [27].
In contrast to the large number of experimental reports, there are
only a few studies that investigate the antiarrhythmic potential of
ranolazine in patients. Ranolazine is known to cause a slight prolonga-
tion of the QTc interval due to the inhibition of IKr [68]. In a small study
in patients with type-3 long-QT syndrome where INa,late is increased,
ranolazine shortened theQT interval in a concentration-dependentman-
ner [54]. Thus the net effect of ranolazine on ventricular repolarization
appears to depend on the amplitude of INa,late.
A seven-day Holter monitoring in ACS patients of the MERLIN-
TIMI 36 study revealed a reduction of ventricular tachycardia (VT)
lasting ≥8 beats in ranolazine treated patients [69]. In a small observa-
tional study ranolazine reduced VT burden and ICD shocks in patients
with antiarrhythmic-drug-refractory VT and previous ICD shocks [70].
Although promising, studies designed to evaluate the potential clinical
role of ranolazine as an antiarrhythmic agent in ventricular arrhythmias
are warranted.
5. INa,late and atrial ﬁbrillation
Atrial ﬁbrillation (AF) causes electrical remodeling of the atria.
Major and well investigated determinants include i) reduced AP dura-
tion, ii) diminished L-type Ca current amplitude, and iii) altered K cur-
rents [71,72]. These changes can explain a reduced refractory period
which provides the possibility of high frequencies during AF.We inves-
tigated atrial myocytes from AF patients and found that INa,late was
increased in myocytes while INa,peak was reduced [38]. Cardiomyocytes
were exposed to ranolazine and showed a reduction of INa,late in cells
from AF patients. Although INa,late integral per beat decreases with in-
creasing frequencies the very high frequency and thus an increase of
the number of INa,late per minute during AF could largely counteract
this effect thereby causing a Na-dependent Ca-overload. Therefore, we
suggest that at least some anti-AF effects of ranolazine are independent
of AP duration and INa,peak modulation in human AF myocytes where
Ca-overload has been shown to be present [73]. Nevertheless, there is
a need for further investigations on INa,late and its relevance for AP dura-
tion vs. Na- and Ca-homeostases especially in models of chronic AF and
thus remodeled myocytes.
Ranolazine is the only potent INa,late inhibitor approved for clinical
purposes and thus the majority of AF studies were performed using
this compound. However, as already mentioned above, ranolazine
also has inhibitory effects on IKr which would prolong the APD in
cardiomyocytes. Indeed, it was shown that ranolazine does not short-
en but rather even slightly prolongs APD leading to prolonged atrial
refractoriness [74]. Since this study did not investigate remodeled
cardiomyocytes, the net effect of ranolazine on APD in most AF pa-
tients with already shortened APD remains a controversial issue [26].
Independent of INa,late inhibition, ranolazine seems to act as an atrial
selective INa,peak inhibitor [74] although selectively inhibiting INa,late in
ventricular myocytes [27]. While the cause of this difference remains
unclear the ability of ranolazine to inhibit INa,peak in atrial myocytes
was largely attributed to electrophysiological differences between atrial
and ventricular myocardium [74]. Reasons for this are a more negative
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potential in atrial myocytes compared to ventricular myocytes.
These electrophysiological differences have been suggested to go along
with an increased percentage of inactivated Na channels at a given
membrane/resting or take off potential which makes them more sensi-
tive to ranolazine.
Accordingly, it was shown that ranolazine produces a marked use-
dependent depression of Na channel parameters in atria but not in
ventricles [74]. In line with this, we could demonstrate that ranolazine
inhibits INa,peak in human atrial myocytes [38].
Several studies revealed that ranolazine exerts potent effects
against AF in multicellular preparations, in vitro hearts, and in animal
models (see Fig. 3). The ﬁrst report indicated that ranolazine pro-
duces concomitant suppression of in vitro acetylcholine-induced AF
[74]. Likewise, in vitro studies using intact porcine hearts and in in
vivo pigs ranolazine was found to increase atrial effective refractory
period, prolong conduction time and decrease acetycholine-induced
duration and inducibility of AF [65,75,76]. Since AF is often associated
with heart failure a recent study investigated ranolazine in an experi-
mental rabbit model of heart failure with present AF. The potent antiar-
rhythmic effect against AFwasmainly explained by the development of
atrial post-repolarization refractoriness and amoderate increase in con-
duction time [77].
AF triggers are considered to be derived from pulmonary veins.
Ranolazine causes a reduction of excitability, conduction slowing,
and suppression of triggered activity in canine pulmonary vein sleeve
preparations [78]. There is also an increasing recognition that either
amiodarone or dronedarone in combination with ranolazine produces
a synergistic atrial-selective depression of Na channel-dependent pa-
rameters and AF in coronary-perfused right atrial and superfused left
atrial pulmonary vein sleeves isolated from dogs [79,80].
There are a few studies that investigated ranolazine in patients
with respect to AF. The already above mentioned MERLIN TIMI-36
trial revealed a reduction of supraventricular tachycardias in patients
that were treated with ranolazine after ACS. Although a very low in-
cidence of AF, subjects treated with ranolazine were less likely to ex-
perience new onset of AF (p = 0.08) [69]. It has to be stated, that this
trial was neither designed nor powerful enough to investigate a valid
effect of ranolazine on AF.
Another study found that 72% of their patients with paroxysmal
AF converted to sinus rhythm after application of 2 g of ranolazine
[81]. The same group also found that ranolazine was helpful in
maintaining sinus rhythm in patients with resistant AF [54]. A pros-
pective randomized pilot study compared the safety and efﬁcacy of
ranolazine plus amiodarone versus amiodarone alone for the conversion5 
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Fig. 3. Ranolazine terminates arrhythmias in an isolated human atrial muscle strip
preparation: Representative recording of an experiment using an isometrically twitching
human atrial muscle strip preparation. Premature contractions were induced using high
extracellular [Ca2+].Application of 10 μmol/L ranolazine potently terminates these
arrhythmias leading to a constant stimulation-dependent contraction pattern.
Modiﬁed from Sossalla et al., J Am Coll Cardiol, 2010.of recent-onset AF. Treatment with ranolazine to standard amiodarone
therapy appeared to be more effective compared to amiodarone alone
for conversion of recent-onset AF (88% vs. 65%, p = 0.056) [82].
Two larger clinical phase II proofs of concept trials currently investi-
gate the effects of ranolazine on AF. On the one hand, the RAFFAELLO
trial (EudraCT-Nr: 2011-002789-18) which is a dose-ranging study test-
ing the efﬁcacy and safety of the three doses of ranolazine versus placebo
in maintaining sinus rhythm after successful electrical cardioversion in
subjects with persistent AF. This study was designed as a randomized,
double-blind, double-dummy, placebo-controlled, dose-ranging trial. In
addition, the HARMONY trial (EudraCT-Nr: 2011-001134-42) evaluates
whether treatment with ranolazine and dronedarone when given alone
and in combination suppresses AF burden in subjects with paroxysmal
AF and implanted pacemakers. This trial is a randomized, double-blind,
placebo-controlled, parallel-arm trial. It remains interesting what new
information these studies will add to the current knowledge.
6. Conclusions
An elevated INa,late causes Na-dependent Ca-overload and hence
electrophysiological changes that are critically involved in ischemia,
systolic and diastolic heart failure, as well as arrhythmias. Ranolazine
as a clinical approved INa,late inhibitor for angina pectoris has been
shown to exert beneﬁcial effects on systolic and diastolic heart failure.
At this time, there is not one recommended and evidence-based agent
for the treatment of diastolic heart failure and therefore a huge clinical
need. Thus, appropriate randomized clinical trials are indicated to
investigate the safety and efﬁcacy of ranolazine in subjects suffering
from heart failure.
Ranolazine has the potential for dual suppression of atrial and ventric-
ular arrhythmias. While ranolazine exerts ventricular antiarrhythmic
effects most likely via inhibition of INa,late a “multichannel inhibitory pro-
ﬁle“ consisting of INa,peak, INa,late, and IKr blockade is regarded to be respon-
sible for its anti-AF effects. Future work should concentrate on these
detailed pharmacodynamic actions of ranolazine to terminate or prevent
AF. Up to now clinical data regarding antiarrhythmic effects are sparse.
Therefore prospective randomized trials are currently recruiting patients
with a focus on the role of ranolazine in AF in order to corroborate the ex-
perimental and preliminary clinical ﬁndings.
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